Profile data is unavailable for this security.
About the company
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
- Revenue in USD (TTM)1.11bn
- Net income in USD-203.88m
- Incorporated2025
- Employees2.40k
- LocationTempus AI Inc600 West Chicago Avenue, Suite 510CHICAGO 60654United StatesUSA
- Websitehttps://investors.tempus.com/
More ▼
Mergers & acquisitions
| Acquired company | TEM:NSQ since announced | Transaction value |
|---|---|---|
| PaigeAI Inc | -29.74% | 81.25m |
Data delayed at least 15 minutes, as of Feb 11 2026 15:05 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Belite Bio Inc (ADR) | 0.00 | -49.38m | 6.64bn | 25.00 | -- | 38.61 | -- | -- | -1.55 | -1.55 | 0.00 | 4.58 | 0.00 | -- | -- | 0.00 | -36.85 | -- | -36.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.26 | -- | -- | -- |
| Vaxcyte Inc | 0.00 | -657.20m | 7.75bn | 414.00 | -- | 2.47 | -- | -- | -4.84 | -4.84 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -19.53 | -26.00 | -20.51 | -27.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.33 | -- | 151.05 | -- |
| Nuvalent Inc | 0.00 | -381.44m | 7.88bn | 218.00 | -- | 8.73 | -- | -- | -5.32 | -5.32 | 0.00 | 11.70 | 0.00 | -- | -- | 0.00 | -35.18 | -25.32 | -37.61 | -26.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -106.59 | -- | -- | -- |
| Cytokinetics, Inc. | 87.21m | -751.94m | 7.93bn | 498.00 | -- | -- | -- | 90.92 | -6.31 | -6.31 | 0.7328 | -4.27 | 0.0607 | -- | 85.00 | 175,122.50 | -52.35 | -45.50 | -57.39 | -50.38 | -- | -- | -862.21 | -748.37 | -- | -14.45 | 1.96 | -- | 145.34 | -7.22 | -12.03 | -- | 8.32 | -- |
| Praxis Precision Medicines Inc | 7.46m | -273.04m | 8.78bn | 116.00 | -- | 19.75 | -- | 1,176.93 | -12.90 | -12.90 | 0.3533 | 16.23 | 0.0184 | -- | -- | 64,336.21 | -67.20 | -70.37 | -75.12 | -79.85 | -- | -- | -3,658.53 | -6,809.15 | -- | -- | 0.00 | -- | 249.53 | -- | -48.30 | -- | -- | -- |
| Arrowhead Pharmaceuticals Inc | 1.09bn | 202.27m | 8.81bn | 711.00 | 40.83 | 15.21 | 34.06 | 8.08 | 1.54 | 1.54 | 7.90 | 4.14 | 0.8335 | -- | 9.86 | 1,534,432.00 | 17.84 | -25.96 | 21.44 | -30.82 | -- | -- | 21.41 | -76.01 | -- | 5.91 | 0.5068 | -- | 23,258.15 | 56.63 | 99.73 | -- | 13.66 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.02bn | -83.48m | 8.92bn | 18.60k | -- | 2.62 | 25.67 | 2.22 | -1.56 | -1.56 | 80.18 | 69.20 | 0.5186 | 8.23 | 5.41 | 216,328.20 | -1.03 | 5.12 | -1.20 | 6.01 | 34.68 | 36.56 | -1.98 | 9.47 | 1.10 | 3.18 | 0.388 | 0.00 | -1.92 | 9.09 | -97.83 | -47.25 | 10.64 | -- |
| Tempus AI Inc | 1.11bn | -203.88m | 9.94bn | 2.40k | -- | 19.57 | -- | 8.99 | -1.18 | -1.18 | 6.45 | 2.86 | 0.6795 | 9.29 | 5.15 | 460,524.20 | -12.53 | -53.69 | -15.38 | -72.10 | 61.73 | 45.68 | -18.45 | -84.29 | 3.12 | -3.83 | 0.7104 | -- | 30.38 | 62.05 | -180.61 | -- | 5.36 | -- |
| BIO-TECHNE Corp | 1.22bn | 79.96m | 10.14bn | 3.10k | 127.67 | 5.02 | 55.18 | 8.34 | 0.5076 | 0.5076 | 7.74 | 12.90 | 0.4682 | 2.06 | 6.04 | 392,121.60 | 3.08 | 7.62 | 3.27 | 8.13 | 66.60 | 67.49 | 6.58 | 16.74 | 3.08 | 56.92 | 0.1145 | 26.72 | 5.23 | 10.55 | -56.35 | -20.37 | -9.74 | -4.36 |
| Madrigal Pharmaceuticals Inc | 740.64m | -289.13m | 10.87bn | 528.00 | -- | 17.37 | -- | 14.68 | -13.01 | -13.01 | 33.39 | 27.56 | 0.6082 | 0.9008 | 10.30 | 1,402,727.00 | -23.74 | -68.48 | -30.98 | -85.32 | 95.25 | -- | -39.04 | -876.55 | 3.26 | -- | 0.3519 | -- | -- | -- | -24.69 | -- | 106.52 | -- |
| ICON PLC | 8.10bn | 599.48m | 11.04bn | 39.80k | 19.54 | 1.18 | 11.17 | 1.36 | 7.40 | 7.40 | 101.04 | 122.25 | 0.4806 | -- | 3.00 | 193,379.50 | 3.56 | 3.70 | 4.33 | 4.46 | 28.15 | 29.00 | 7.40 | 7.41 | -- | 5.94 | 0.2675 | -- | 1.99 | 24.17 | 29.26 | 16.18 | 27.11 | -- |
| Summit Therapeutics Inc | 0.00 | -921.62m | 11.35bn | 159.00 | -- | 59.05 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2583 | 0.00 | -- | -- | 0.00 | -241.08 | -78.31 | -287.72 | -86.84 | -- | -- | -- | -31,307.77 | -- | -- | 0.00 | -- | -- | -- | 64.01 | -- | -16.43 | -- |
| Exelixis Inc | 2.29bn | 677.90m | 11.52bn | 1.15k | 18.09 | 5.33 | 16.28 | 5.04 | 2.38 | 2.38 | 8.00 | 8.06 | 0.7913 | 3.19 | 7.90 | 1,994,959.00 | 23.44 | 9.51 | 27.03 | 10.77 | 96.63 | 96.32 | 29.63 | 15.61 | 3.68 | -- | 0.00 | 0.00 | 18.49 | 17.51 | 150.89 | 10.18 | 17.25 | -- |
| Medpace Holdings Inc | 2.53bn | 451.12m | 12.65bn | 6.20k | 29.17 | 27.50 | 26.41 | 5.00 | 15.29 | 15.29 | 85.68 | 16.22 | 1.24 | -- | 7.24 | -- | 22.13 | 18.52 | 55.42 | 37.53 | 30.06 | 29.60 | 17.83 | 17.15 | -- | -- | -- | -- | 19.97 | 22.27 | 11.57 | 25.50 | 0.0102 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -3.58m | 13.19bn | 12.00 | -- | 2,714.45 | -- | -- | -0.0073 | -0.0073 | 0.00 | 0.0098 | 0.00 | -- | -- | 0.00 | -50.50 | -53.93 | -53.75 | -65.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.68 | -- | 5.32 | -- |
Data as of Feb 11 2026. Currency figures normalised to Tempus AI Inc's reporting currency: US Dollar USD
29.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 9.47m | 5.48% |
| Baillie Gifford & Co.as of 31 Dec 2025 | 8.74m | 5.06% |
| ARK Investment Management LLCas of 30 Sep 2025 | 7.18m | 4.15% |
| GC Wealth Management RIA LLCas of 31 Dec 2025 | 6.76m | 3.91% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 5.38m | 3.11% |
| Amova Asset Management Co., Ltd.as of 31 Dec 2025 | 3.50m | 2.03% |
| Amova Asset Management Americas, Inc.as of 30 Sep 2025 | 3.46m | 2.00% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2025 | 2.28m | 1.32% |
| D. E. Shaw & Co. LPas of 30 Sep 2025 | 2.03m | 1.17% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 1.78m | 1.03% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
